ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,522,668 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.34 billion. Gsk has a price to earnings ratio (PE ratio) of 14.27.

Gsk Share Discussion Threads

Showing 18501 to 18524 of 33075 messages
Chat Pages: Latest  747  746  745  744  743  742  741  740  739  738  737  736  Older
DateSubjectAuthorDiscuss
03/12/2018
22:47
Thank goodness for guaranteed stops!
toffeeman
03/12/2018
22:03
VS AZN.Pittyfull.


free stock charts from uk.advfn.com

tim 3
03/12/2018
21:19
Rom, read Bloombergs report on this tonight, zejula or whatever its called is no blockbuster, serious side effects, behind the competition and just hasnt taken off, in fact there are serious doubts about parp technology now. I dont need exciting investments i want profitable ones, gsk has been poorly managed for twenty years and so it goes on, share price ever pathetic.
porsche1945
03/12/2018
21:01
1518p close stateside
philanderer
03/12/2018
20:59
Am I the only one who thinks that it is bonkers that the market cap of GSK has fallen by 1.5x more that the cost of this acquisition, how can that make any sense?
spyder
03/12/2018
20:55
GSK have said in the RNS they expect to pay the 80p dividend again



'Crown Labs Acquires Rights to Select Brands from GlaxoSmithKline'

philanderer
03/12/2018
20:19
You cannot possibly compare Shire's acquisition of Baxalta to this, Baxalta was larger than Shire. Tesaro is tiny compared to GSK and they are buying it at a price not much less than it was trading at as recently as January. Yes is quite an expensive price in the current market, but this was not an uncontested acquisition and Dr Hal Barron has clearly found enough evidence to convince the board to go for the deal.

What are they getting for the money? - a specialist oncology team, proven PARP inhibitor technology, a likely blockbuster drug in Zejula, at least two impressive early stage treatments, as well as an experienced oncology sales team and assets in Boston.

romeike
03/12/2018
19:51
With the Novartis deal and this 4 billion it's a lot of cost. Plus Gsk's debt ...... is the divi in tact ?
mj19
03/12/2018
19:42
Pharmas are high risk; it is the nature of the sector. If you don't like risk then it is a not a sector for you.

It is also one of the most exciting sectors with many many brilliant people.

alphorn
03/12/2018
19:27
just the sort of overpriced lunacy Shire got into and look what happened to them, I think Terry Smith is right, you cant invest in pharma, just too dodgy, nonsense like this all the time, expect more falls, bad deal.
porsche1945
03/12/2018
18:20
FT

"..Liberum said the drug had struggled to carve out a market against competitors such as AstraZeneca and Merck’s Lynparza, saying: “At this point Tesaro looks to be second best in the PARP space and while this can be turned around with expansion in other indications, we have limited evidence thus far that this will be the case.”

philanderer
03/12/2018
18:20
It needs to settle. Tomorrow's another day.
tradermichael
03/12/2018
18:18
Wall St Journal

Glaxo investors appeared cool on the deal Monday, with its shares falling almost 8%. Analysts expressed surprise at the deal, pointing to the apparent lack of overlap with Glaxo’s existing cancer pipeline and Zejula’s less favorable side-effect profile. Tesaro’s stock soared nearly 59%.

Glaxo’s Chief Scientific Officer Hal Barron said a clinical study that is due to publish results in the first half of next year could expand Zejula’s use to women at an earlier stage of ovarian cancer, boosting sales.

Dr. Barron also pointed to a growing body of research suggesting that PARP inhibitors combined with other cancer drugs could prove powerful in treating a range of cancers that exhibit a particular genetic defect.

“This is just the tip of the iceberg,” he said. “We’ll start learning about cancers with these defects and how to treat them.” He said Glaxo would test out Zejula in combination with drugs in its own cancer-drug pipeline as well as those under development at Tesaro.

full article:

philanderer
03/12/2018
17:45
Market hates the deal, going by the shareprice.
montyhedge
03/12/2018
17:44
I suspect that Hal Baron and Luke Miels had more than a passive involvement in this acquisition and also a better understanding than Monte of what could prove a game changing move for GSK - Emma gets my vote !
ianood
03/12/2018
17:40
Totally agree, ego-trip to show she can do a large deal. Crazy.
montyhedge
03/12/2018
16:36
Most of the gains achieved since early Feb now undone in one huge gamble. This woman Walmsley is beginning to look like a disaster in the making. She seems hell bent on destroying shareholder's value. Another one of these ego-trippers intent on proving she is a deal-maker whatever the cost. Now a rights or div cut will be on the cards.
bend1pa
03/12/2018
16:30
Romeike - I agree. This is a bold and risky move but is exactly the sort of thing GSK should be doing. Just a shame it has been greeted by a massive negative overreaction
rikky72
03/12/2018
16:30
Even good companies bought at the wrong price is a bad investment.She's overpaid.
montyhedge
03/12/2018
16:25
Anyone can do deals. It is doing deals at right price she should focus on
watfordhornet
03/12/2018
16:20
...made me smile too, oh, and I think the markets have over-reacted as usual .
redips2
03/12/2018
16:16
Paper loss of 35000 pounds for some.
abdullla
03/12/2018
16:09
zho3 Dec '18 - 15:18 - 18468 of 18477
0 2 0
I sometimes need a PARP inhibitor, especially after a few pints of Guinness.



Sorry, I'll get my coat.


tee hee

davemac3
03/12/2018
15:56
She won't do that, she wants to prove she can do deals. Walmsley would look stupid. But this is way to expensive deal. 1275p my target.
montyhedge
Chat Pages: Latest  747  746  745  744  743  742  741  740  739  738  737  736  Older

Your Recent History

Delayed Upgrade Clock